Bellevue Life Sciences Acquisition Balance Sheet Health
Financial Health criteria checks 0/6
Bellevue Life Sciences Acquisition has a total shareholder equity of $-4.3M and total debt of $222.0K, which brings its debt-to-equity ratio to -5.2%. Its total assets and total liabilities are $37.3M and $41.6M respectively.
Key information
-5.2%
Debt to equity ratio
US$222.00k
Debt
Interest coverage ratio | n/a |
Cash | US$3.64k |
Equity | -US$4.31m |
Total liabilities | US$41.58m |
Total assets | US$37.27m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BLAC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BLAC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BLAC has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BLAC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: BLAC's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if BLAC's interest payments on its debt are well covered by EBIT.